Skip to Main Content

For the past few weeks, a U.S. bankruptcy court has heard objections to a plan to transform Purdue Pharma into a public benefit company, which would be run on behalf of the numerous communities that have pursued the drug maker for compensation for the cost of the opioid crisis.

The notion is part of an $8.3 billion settlement of criminal and civil charges reached with the Department of Justice. And at a recent hearing, U.S. Bankruptcy Court Judge Robert Drain cited a new book by an historian to express tentative support for the proposal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!